Maintenance of antiangiogenic and antitumor effects by orally active low-dose capecitabine for long-term cancer therapy.
Zhang Y, Sun M, Huang G, Yin L, Lai Q, Yang Y, Xing X, Yu G, Sun Y, Wang X, Nie G, Liu Y, Cao Y.
Zhang Y, et al. Among authors: sun m, sun y.
Proc Natl Acad Sci U S A. 2017 Jun 27;114(26):E5226-E5235. doi: 10.1073/pnas.1705066114. Epub 2017 Jun 12.
Proc Natl Acad Sci U S A. 2017.
PMID: 28607065
Free PMC article.